ESMO 2025 | Optimizing patient selection for combination therapies in oncology
Racha Kussaibati, MD, University Hospitals Birmingham, Birmingham, UK, highlights the rapid expansion of combination treatments and the importance of identifying the right patients for the right treatment, considering the potential increased side effects and toxicities. Clinical trials need to involve nurses and patients in the design phase to reflect real-world needs and address broader issues related to combination treatments, immunotherapy, and subcutaneous preparations. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think it’s very exciting. It’s all expanding very rapidly. And I think we need to think about who are the right patients for the right treatment when it comes to combinations. Of course, combinations come with the cost of sometimes more side effects and more toxicities. So we have to establish trials that are designed to address these issues. And I think one of the key messages from my presentation was that at the time of conception of clinical trials, we need to involve nurses...
I think it’s very exciting. It’s all expanding very rapidly. And I think we need to think about who are the right patients for the right treatment when it comes to combinations. Of course, combinations come with the cost of sometimes more side effects and more toxicities. So we have to establish trials that are designed to address these issues. And I think one of the key messages from my presentation was that at the time of conception of clinical trials, we need to involve nurses. We need to involve patients when we design these clinical trials so that we are reflecting the real-world needs as opposed to just the scientific and data-heavy needs, because then we will be able to address the wider issues when it comes to combination treatments, immunotherapy, and subcutaneous preparations as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
